Hudbay Minerals (NYSE:HBM) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 133.33 percent decrease over earnings of $0.15 per share from the same period last year.
Credit Suisse Reiterates Outperform on AbCellera Biologics, Maintains $34 Price Target
Credit Suisse analyst Tiago Fauth reiterates AbCellera Biologics (NASDAQ:ABCL) with a Outperform and maintains $34 price target.